Anti-actriib antibody and use thereof
By developing a variety of anti-ActRIIB antibodies and their antigen-binding fragments, the problem of insufficient treatment options for existing anti-ActRII antibodies has been solved, achieving effective regulation of muscle growth and fat metabolism and providing a wider range of clinical treatment options.
Patent Information
- Application Number
- PCT/CN2026/097056
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
The existing anti-ActRII antibodies still require more treatment options in clinical practice to address diseases such as muscle atrophy, muscular dystrophy, cachexia, as well as related diseases such as obesity and metabolic syndrome.
A variety of anti-ActRIIB antibodies and their antigen-binding fragments have been developed, containing specific HCDR and LCDR amino acid sequences, to block the binding of ActRIIB to its ligands, affect downstream signaling pathways, and regulate muscle growth and lipid metabolism.
It provides a wider range of clinical treatment options, effectively regulates muscle growth and fat metabolism, and demonstrates good therapeutic effects and safety.
Smart Images

Figure CN2026097056_19112026_PF_FP_ABST
Abstract
Description
Anti-ActRIIB antibodies and their applications Technical Field
[0001] This disclosure belongs to the field of biomedical technology, specifically relating to anti-ActRIIB antibodies and their applications. Background Technology
[0002] Activin type II receptors (ActRIIs), as core mediators of the transforming growth factor β (TGF-β) superfamily signaling pathway, play a crucial role in cellular signaling networks. This family includes two structurally homologous subtypes—activin type II receptor A (ActRIIA / ACVR2A) and activin type II receptor B (ActRIIB / ACVR2B). Both consist of an extracellular ligand-binding domain, a transmembrane domain, and an intracellular kinase domain. Through highly conserved domains, they specifically bind to ligands, initiating downstream signaling cascades.
[0003] ActRII signaling activation depends on precise binding to specific ligands, whose ligand spectrum is known to include multiple family members such as activins (e.g., Activin A) and growth differentiation factors (e.g., GDF8 / myostatin, GDF11). After binding to the ligand, ActRII recruits and phosphorylates TGF-β superfamily type I receptors, thereby activating downstream Smad2 / 3 signaling molecules. Phosphorylated Smad2 / 3 forms a heterologous complex with Smad4, which translocates into the cell nucleus to regulate the transcription of target genes, ultimately participating in several key physiological processes such as muscle growth regulation, lipid metabolism homeostasis, and immune microenvironment homeostasis.
[0004] In muscle tissue, activation of the ActRII signaling pathway has a clear negative regulatory effect. Studies have confirmed that after the ligand GDF8 binds to ActRIIB, it can inhibit the expression of myocyte-specific transcription factors (such as MyoD and MyoG) through the Smad signaling pathway, hindering myoblast proliferation and differentiation, while promoting the activation of myofibril degradation-related genes (such as Atrogin-1 and MuRF1), ultimately leading to muscle atrophy. This mechanism plays a central role in muscle loss in diseases such as muscular dystrophy and cachexia.
[0005] In adipose tissue, the ActRII signaling pathway promotes adipogenesis. After Activin A binds to ActRII, it can upregulate the expression of key adipogenic differentiation factors such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT enhancer-binding protein α (C / EBPα) through Smad3 signaling, accelerating the transformation of preadipocytes into mature adipocytes. At the same time, it promotes the activity of lipid synthesis-related enzymes such as fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), enhancing the lipid storage capacity of adipose tissue. Abnormal activation of ActRII is closely related to the occurrence of obesity and metabolic syndrome.
[0006] Anti-ActRII antibodies are already under development in clinical practice, but new anti-ActRII antibodies still need to be developed to provide more clinical treatment options.
[0007] Invention Summary
[0008] This disclosure provides anti-ActRIIB antibodies and their antigen-binding fragments, as well as related nucleic acids, vectors, cells, pharmaceutical compositions, preparation methods, and uses encoding the provided antibodies and their antigen-binding fragments.
[0009] In one aspect, this disclosure provides an anti-ActRIIB antibody or an antigen-binding fragment thereof, comprising:
[0010] (1) HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:2, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:37; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:2, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:37;
[0011] (2) HCDR1 containing the amino acid sequence shown in SEQ ID NO:4, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:6, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:38, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:39; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:4, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:6, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:38, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:39;
[0012] (3) HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40;
[0013] (4) HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:7, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:7, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40;
[0014] (5) HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:9, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:41, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:43; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:9, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:41, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:43;
[0015] (6) HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:11, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:44, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:45; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:11, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:44, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:45;
[0016] (7) HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:47, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:47, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48;
[0017] (8) HCDR1 containing the amino acid sequence shown in SEQ ID NO:15, HCDR2 containing the amino acid sequence shown in SEQ ID NO:16, HCDR3 containing the amino acid sequence shown in SEQ ID NO:17, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:15, HCDR2 containing the amino acid sequence shown in SEQ ID NO:16, HCDR3 containing the amino acid sequence shown in SEQ ID NO:17, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48;
[0018] (9) HCDR1 containing the amino acid sequence shown in SEQ ID NO:18, HCDR2 containing the amino acid sequence shown in SEQ ID NO:19, HCDR3 containing the amino acid sequence shown in SEQ ID NO:20, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:51, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:18, HCDR2 containing the amino acid sequence shown in SEQ ID NO:19, HCDR3 containing the amino acid sequence shown in SEQ ID NO:20, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:51, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48;
[0019] (10) HCDR1 containing the amino acid sequence shown in SEQ ID NO:21, HCDR2 containing the amino acid sequence shown in SEQ ID NO:22, HCDR3 containing the amino acid sequence shown in SEQ ID NO:23, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:21, HCDR2 containing the amino acid sequence shown in SEQ ID NO:22, HCDR3 containing the amino acid sequence shown in SEQ ID NO:23, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48;
[0020] (11) HCDR1 containing the amino acid sequence shown in SEQ ID NO:24, HCDR2 containing the amino acid sequence shown in SEQ ID NO:25, HCDR3 containing the amino acid sequence shown in SEQ ID NO:26, LCDR1 containing the amino acid sequence shown in SEQ ID NO:52, LCDR2 containing the amino acid sequence shown in SEQ ID NO:53, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:54; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:24, HCDR2 containing the amino acid sequence shown in SEQ ID NO:25, HCDR3 containing the amino acid sequence shown in SEQ ID NO:26, LCDR1 containing the amino acid sequence shown in SEQ ID NO:52, LCDR2 containing the amino acid sequence shown in SEQ ID NO:53, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:54;
[0021] (12) HCDR1 containing the amino acid sequence shown in SEQ ID NO:27, HCDR2 containing the amino acid sequence shown in SEQ ID NO:28, HCDR3 containing the amino acid sequence shown in SEQ ID NO:29, LCDR1 containing the amino acid sequence shown in SEQ ID NO:55, LCDR2 containing the amino acid sequence shown in SEQ ID NO:56, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:57; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:27, HCDR2 containing the amino acid sequence shown in SEQ ID NO:28, HCDR3 containing the amino acid sequence shown in SEQ ID NO:29, LCDR1 containing the amino acid sequence shown in SEQ ID NO:55, LCDR2 containing the amino acid sequence shown in SEQ ID NO:56, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:57;
[0022] (13) HCDR1 containing the amino acid sequence shown in SEQ ID NO:30, HCDR2 containing the amino acid sequence shown in SEQ ID NO:31, HCDR3 containing the amino acid sequence shown in SEQ ID NO:32, LCDR1 containing the amino acid sequence shown in SEQ ID NO:58, LCDR2 containing the amino acid sequence shown in SEQ ID NO:59, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:60; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:30, HCDR2 containing the amino acid sequence shown in SEQ ID NO:31, HCDR3 containing the amino acid sequence shown in SEQ ID NO:32, LCDR1 containing the amino acid sequence shown in SEQ ID NO:58, LCDR2 containing the amino acid sequence shown in SEQ ID NO:59, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:60;
[0023] (14) HCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:33, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:34, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:61, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:62; or, HCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:33, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:34, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:61, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:62; or
[0024] (15) HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:63; or, HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:63.
[0025] In one aspect, this disclosure provides an anti-ActRIIB antibody or an antigen-binding fragment thereof, comprising:
[0026] (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:65;
[0027] (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:66, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:67;
[0028] (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:68, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:69;
[0029] (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:70, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:71;
[0030] (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:72, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:73;
[0031] (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:74, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:75;
[0032] (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:76, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:77.
[0033] (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:78, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:79;
[0034] (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:80, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:81;
[0035] (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:82, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:83;
[0036] (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:84, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:85;
[0037] (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:86, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:87.
[0038] (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:88, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:89;
[0039] (14) HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:90, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:91; or
[0040] (15) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:92, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:93;
[0041] The CDR mentioned therein is defined, for example, according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
[0042] In one aspect, this disclosure provides isolated nucleic acids containing nucleotide sequences encoding the anti-ActRIIB antibody or its antigen-binding fragment as described in this disclosure.
[0043] In one respect, this disclosure provides a carrier containing the nucleic acid described herein.
[0044] In one respect, this disclosure provides a host cell containing the nucleic acid or the vector described herein.
[0045] In one aspect, this disclosure provides a fusion protein comprising the anti-ActRIIB antibody of this disclosure or an antigen-binding fragment thereof.
[0046] In one aspect, this disclosure provides antibody-drug conjugates comprising the anti-ActRIIB antibody of this disclosure or its antigen-binding fragment.
[0047] In one aspect, this disclosure provides an anti-ActRIIB chimeric antigen receptor comprising the anti-ActRIIB antibody of this disclosure or an antigen-binding fragment thereof.
[0048] In one aspect, this disclosure provides engineered immune effector cells that contain the chimeric antigen receptor of this disclosure.
[0049] On the other hand, this disclosure provides a method for preparing the anti-ActRIIB antibody or its antigen-binding fragment as described herein, comprising culturing the host cells to express the anti-ActRIIB antibody or its antigen-binding fragment, and isolating and purifying the anti-ActRIIB antibody or its antigen-binding fragment in the system.
[0050] On the other hand, this disclosure provides pharmaceutical compositions comprising the anti-ActRIIB antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate or the engineered immune effector cells, and pharmaceutically acceptable excipients.
[0051] On the other hand, this disclosure provides the use of the anti-ActRIIB antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate, the engineered immune effector cells, or the pharmaceutical composition in the preparation of a medicament for treating diseases related to ActRII expression or ActRII signaling.
[0052] On the other hand, this disclosure provides a method for treating diseases associated with ActRII expression or ActRII signaling, comprising administering to a subject the anti-ActRIIB antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate, the engineered immune effector cells, or the pharmaceutical composition.
[0053] On the other hand, this disclosure provides the use of the anti-ActRIIB antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate, the engineered immune effector cells, or the pharmaceutical composition in the treatment of diseases related to ActRII expression or ActRII signaling.
[0054] The anti-ActRIIB antibody or its antigen-binding fragment disclosed herein demonstrates good efficacy and safety in treating diseases related to ActRII expression or ActRII signaling. Attached Figure Description
[0055] Figures 1A-1H illustrate the protein-based binding activity of anti-ActRIIB antibodies to ActRIIA or ActRIIB.
[0056] Figures 2A-2B illustrate the cell-based binding activity of anti-ActRIIB antibodies.
[0057] Figures 3A-3H illustrate the protein-based blocking activity of anti-ActRIIB antibodies against the binding of ActRIIA to Activin A;
[0058] Figures 4A-4H illustrate the protein-based blocking activity of anti-ActRIIB antibodies against the binding of ActRIIB to Activin A;
[0059] Figures 5A-5D illustrate the cell-based activity of anti-ActRIIB antibodies in blocking the binding of ActRIIB to Activin A;
[0060] Figures 6A-6D illustrate the cell-based activity of anti-ActRIIB antibodies in blocking the binding of ActRIIB to GDF8;
[0061] Figure 7 shows the pharmacokinetic characteristics of the anti-ActRIIB antibody in cynomolgus monkeys.
[0062] Invention Details
[0063] Definitions and Explanations
[0064] Unless otherwise stated, the following terms as used in this disclosure have the following meanings. A particular term should not be considered uncertain or unclear unless specifically defined, but should be understood in accordance with its ordinary meaning in the art. When a trade name appears herein, it is intended to refer to the corresponding product or its active ingredient.
[0065] “Activin type II receptor A” (also known as “Activin Receptor Type IIA”, “ActRIIA”, or “ACVR2A”, which are used interchangeably in this disclosure) is a type II transmembrane receptor protein belonging to the transforming growth factor-β (TGF-β) superfamily. In this disclosure, “ActRIIA” refers to naturally occurring ActRIIA polypeptides (e.g., Uniprot: P27037), its variants (including but not limited to point mutants, truncated forms, and fusion proteins), or biologically active fragments having at least 80% sequence homology with their ligand-binding domains.
[0066] “Activin type II receptor B” (also known as “Activin Receptor Type IIB”, “ActRIIB”, or “ACVR2B”, which are used interchangeably in this disclosure) is a type II transmembrane receptor protein belonging to the transforming growth factor-β (TGF-β) superfamily. In this disclosure, “ActRIIB” refers to a naturally occurring ActRIIB polypeptide (e.g., Uniprot: Q13705), its variants (including but not limited to point mutants, truncated versions, and fusion proteins), or a biologically active fragment having at least 80% sequence homology with its ligand-binding domain.
[0067] The term "antibody" is used in the broadest sense to encompass a variety of natural and artificial antibodies, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies (e.g., bispecific antibodies, trispecific antibodies), and various antibody structures of single-chain antibodies, as long as they exhibit the desired antigen-binding activity.
[0068] The term “antigen-binding fragment” refers to one or more fragments of an antibody that retain the function of specifically binding to an antigen. Examples covered by the term “antigen-binding fragment” include: (i) Fab fragments: monovalent fragments consisting of VL, VH, CL, and CH1 domains; (ii) F(ab')2 fragments, bivalent fragments containing two Fab fragments connected by a disulfide bridge in the hinge region; (iii) Fd fragments consisting of VH and CH1 domains; (iv) Fv fragments consisting of VL and VH domains of an antibody single arm; (v) dAb fragments consisting of VH domains (see Ward et al., Nature. 341:544-546 (1989)); (vi) separated complementarity-determining regions (CDRs); (vii) nanobodies; and single-chain Fv (scFv).
[0069] The term "variable domain" or "variable region" refers to a domain of an antibody involved in the binding of the antibody to an antigen. For example, natural four-chain antibodies (e.g., derived from humans, mice, etc.) have a heavy chain variable region (also called a heavy chain variable domain, VH, or VH domain) and a light chain variable region (also called a light chain variable domain, VL, or VL domain). In most cases, each variable domain of a natural antibody essentially consists of four "frame regions (FRs)" and three "complementarity-determining regions (CDRs)." The four frame regions are referred to as frame region 1 (or FR1), frame region 2 (or FR2), frame region 3 (or FR3), and frame region 4 (or FR4); these frame regions are separated by three complementarity-determining regions, referred to in the art and hereinafter as complementarity-determining regions 1 (or CDR1), 2 (or CDR2), and 3 (or CDR3), respectively. Therefore, the general structure of a variable domain can be represented as: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Variable domains endow antibodies with antigen specificity because they have antigen-binding sites.
[0070] The term "complementarity-determining region" (CDR) is also known as the "hypervariant region" (HVR). Natural four-chain antibodies typically contain six CDRs: three in the heavy chain variable region, namely heavy chain CDR1 (HCDR1), heavy chain CDR2 (HCDR2), and heavy chain CDR3 (HCDR3); and three in the light chain variable region, namely light chain CDR1 (LCDR1), light chain CDR2 (LCDR2), and light chain CDR3 (LCDR3).
[0071] Currently, there are many methods for defining CDRs. The Kabat definition, based on sequence variability, is the most commonly used; while the Chothia definition is based on the position of structural loops. The AbM definition is a compromise between the Kabat and Chothia definitions and is used by Oxford Molecular's AbM antibody modeling software. The "contact" definition of a CDR is based on the analysis of available complex crystal structures. Other definitions include IMGT, CCG, etc. However, it should be noted that the boundaries of CDRs for the same antibody variable region obtained based on different methods may differ; that is, the CDR sequences for the same antibody variable region defined by different methods may vary. Therefore, when referring to antibodies defined by a specific CDR sequence, the scope of the antibody also includes antibodies defined by CDR sequences of any other definition (e.g., one or a combination of Kabat, IMGT, Chothia, Contact, AbM, CCG, etc.).
[0072] The term “treatment” means administering the compounds (e.g., antibodies) or pharmaceutical compositions described in this disclosure to prevent, improve, or eliminate a disease or one or more symptoms associated with said disease, including but not limited to: (i) preventing the occurrence of a disease or disease state in mammals, particularly when such mammals are susceptible to the disease state but have not yet been diagnosed with it; (ii) suppressing a disease or disease state, i.e., halting its development; (iii) alleviating a disease or disease state, even if the disease or disease state subsides; and (iv) reducing any direct or indirect pathological consequences of the disease or disease state.
[0073] The term “therapeutic effective amount” means (i) the amount of the disclosed compound used to treat or prevent a particular disease, condition, or disorder; (ii) to reduce, improve, or eliminate one or more symptoms of a particular disease, condition, or disorder; or (iii) to prevent or delay the onset of one or more symptoms of a particular disease, condition, or disorder described herein. The amount of the disclosed anti-ActRIIB antibody or its antigen-binding fragment, fusion protein, antibody-drug conjugate, engineered immune effector cell, or pharmaceutical composition constituting a “therapeutic effective amount” may vary depending on factors such as the compound or pharmaceutical composition and its ability to elicit a desired response in an individual, the disease state and its severity, the route of administration, and the age, sex, and weight of the mammal to be treated.
[0074] The term "pharmaceutical acceptable" refers to compounds, materials, compositions, and / or dosage forms that, within the bounds of reliable medical judgment, are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0075] The term "excipient" refers to any component other than the active ingredient (e.g., the antibody of this disclosure). The selection of excipients will depend to a great extent on factors such as the specific method of administration, the efficacy of the excipient in terms of solubility and stability, and the nature of the dosage form.
[0076] The term "isolated" refers to a target compound that has been isolated from its natural environment, such as an antibody or its antigen-binding fragment or nucleic acid.
[0077] As used in this article, the term "EC" 50 "IC50" refers to the concentration of a compound at which the induced response is 50% of the maximum response, i.e., half the distance between the maximum response and the baseline. 50 "Hypermodity concentration" (MCC) refers to the concentration of antibody required to achieve 50% inhibition of a biological process. 50 or IC 50It can be measured by ELISA or FACS analysis or any other method known in the art.
[0078] “K D "Refers to the equilibrium dissociation constant, which is the self-dissociation rate constant (k d ) relative binding rate constant (k a (that is, k) d / k a The ratio of K to its molar concentration (M) is expressed as a molar concentration. D The value can be determined using methods well-established in the art. (For determining K) D The preferred method is to use surface plasmon resonance (SPR) technology, preferably using a biosensor system such as the Biacore surface plasmon resonance system for analysis.
[0079] The term "non-binding" refers to the absence of binding to proteins or cells, or to extremely low binding affinity or lack of practical biological significance, or to the presence of K+ binding to proteins or cells as determined by surface plasmon resonance (SPR) technology. D A value of 1.00E-06M or higher, or referring to the EC value of the protein as determined by enzyme-linked immunosorbent assay (ELISA). 50 The value is 50 nM or higher, or it shows very weak binding or no binding in one of the above assay types or equivalent assays.
[0080] The term "identity," also known as consistency, refers to the percentage of amino acid residues in the sequence to be aligned that are identical to those in the specific amino acid sequence shown herein, after aligning the sequence to be aligned with it and, if necessary, introducing vacancies to achieve the maximum percentage of sequence identity, and without considering any conservative substitutions as part of the sequence identity. Amino acid sequence alignment for identity can be performed using various methods within the art, such as BLAST, BLAST-2, etc. Those skilled in the art can determine the appropriate parameters for the aligned sequences, including any algorithm required to achieve maximum alignment across the full length of the compared sequences.
[0081] The term "subject" includes any human or non-human animal. The term "non-human animal" includes all vertebrates, such as mammals and non-mammals, including non-human primates, sheep, goats, dogs, cats, horses, cattle, chickens, amphibians, reptiles, etc. Preferably, the subject according to this disclosure is a human. Unless otherwise stated, the terms "patient" or "subject" may be used interchangeably.
[0082] As used herein, “about” means within the acceptable range of error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” may, in accordance with art practice, mean within one or more standard deviations. Alternatively, “about” may mean a range of up to ±5%, such as fluctuations within ±2%, ±1%, or ±0.5% of a given specific numerical range. When a particular value is given in the scope of this disclosure, unless otherwise stated, “about” shall be understood to mean within the acceptable range of error for that particular value. In this document, unless otherwise stated, the values of step parameters or conditions are implicitly modified by “about”.
[0083] The terms “comprise,” “containing,” and “comprising” and their equivalents (e.g., contain, contains, containing, include, includes, and including) shall be understood as “including but not limited to,” meaning that in addition to the listed elements, components, and steps, other unspecified elements, components, and steps may also be covered.
[0084] In this document, unless the context clearly indicates otherwise, singular terms encompass plural referents, and vice versa.
[0085] Anti-ActRIIB antibody or its antigen-binding fragment
[0086] This disclosure provides an anti-ActRIIB antibody or its antigen-binding fragment, comprising: HCDR1 containing the amino acid sequence shown in SEQ ID NO: 1, 4, 8, 12, 15, 18, 21, 24, 27 or 30; HCDR2 containing the amino acid sequence shown in SEQ ID NO: 2, 5, 9, 11, 13, 16, 19, 22, 25, 28, 31 or 33; HCDR3 containing the amino acid sequence shown in SEQ ID NO: 3, 6, 7, 10, 14, 17, 20, 23, 26, 29, 32 or 34; LCDR1 containing the amino acid sequence shown in SEQ ID NO: 35, 41, 44, 46, 49, 52, 55 or 58; LCDR2 containing the amino acid sequence shown in SEQ ID NO: 36, 38, 42, 47, 50, 51, 53, 56, 59 or 61; and HCDR2 containing the amino acid sequence shown in SEQ ID NO: 1, 4, 8, 12, 15, 18, 21, 24, 27 or 30. LCDR3 with amino acid sequences shown in NO:37, 39, 40, 43, 45, 48, 54, 57, 60, 62 or 63.
[0087] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 of the amino acid sequence shown in SEQ ID NO: 1, 4, 8, 12, 15, 18, 21, 24, 27 or 30; HCDR2 of the amino acid sequence shown in SEQ ID NO: 2, 5, 9, 11, 13, 16, 19, 22, 25, 28, 31 or 33; HCDR3 of the amino acid sequence shown in SEQ ID NO: 3, 6, 7, 10, 14, 17, 20, 23, 26, 29, 32 or 34; LCDR1 of the amino acid sequence shown in SEQ ID NO: 35, 41, 44, 46, 49, 52, 55 or 58; LCDR2 of the amino acid sequence shown in SEQ ID NO: 36, 38, 42, 47, 50, 51, 53, 56, 59 or 61; and SEQ ID LCDR3 with amino acid sequences shown in NO:37, 39, 40, 43, 45, 48, 54, 57, 60, 62 or 63.
[0088] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:2, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:37.
[0089] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:4, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:6, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:38, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:39.
[0090] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40.
[0091] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:7, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40.
[0092] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:9, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:41, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:43.
[0093] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:11, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:44, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:45.
[0094] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:47, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48.
[0095] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:15, HCDR2 containing the amino acid sequence shown in SEQ ID NO:16, HCDR3 containing the amino acid sequence shown in SEQ ID NO:17, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48.
[0096] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:18, HCDR2 containing the amino acid sequence shown in SEQ ID NO:19, HCDR3 containing the amino acid sequence shown in SEQ ID NO:20, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:51, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48.
[0097] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:21, HCDR2 containing the amino acid sequence shown in SEQ ID NO:22, HCDR3 containing the amino acid sequence shown in SEQ ID NO:23, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48.
[0098] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:24, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:25, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:26, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:52, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:53, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:54.
[0099] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:27, HCDR2 containing the amino acid sequence shown in SEQ ID NO:28, HCDR3 containing the amino acid sequence shown in SEQ ID NO:29, LCDR1 containing the amino acid sequence shown in SEQ ID NO:55, LCDR2 containing the amino acid sequence shown in SEQ ID NO:56, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:57.
[0100] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:30, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:32, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:58, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:59, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:60.
[0101] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:33, HCDR3 containing the amino acid sequence shown in SEQ ID NO:34, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:61, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:62.
[0102] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:63.
[0103] This disclosure also provides an anti-ActRIIB antibody or its antigen-binding fragment comprising: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO: 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, or 92, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO: 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, or 93. The CDRs are defined, for example, according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
[0104] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:64, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:65.
[0105] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:66, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:67.
[0106] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:68, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:69.
[0107] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:70, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:71.
[0108] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:72, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:73.
[0109] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:74, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:75.
[0110] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:76, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:77.
[0111] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:78, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:79.
[0112] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:80, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:81.
[0113] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:82, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:83.
[0114] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:84, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:85.
[0115] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:86, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:87.
[0116] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:88, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:89.
[0117] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:90, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:91.
[0118] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:92, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:93.
[0119] In some implementations, the CDR is defined according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
[0120] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 64, 66, 68, 70, 72, 74, 76, 78, 80, or 92.
[0121] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85%, 87%, 98%, 99%, or 100% identical.
[0122] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequences shown in SEQ ID NO: 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, or 92, and an amino acid sequence identical to that shown in SEQ ID NO: 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, or 92. The amino acid sequences shown in NO:65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, or 93 have light chain variable regions with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity.
[0123] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:64. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:65. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:65. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:2, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:37.
[0124] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:66. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:67. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:67. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:4, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:6, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:38, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:39.
[0125] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:68. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:69. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:68, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:69. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40.
[0126] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:70. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:71. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:71. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:7, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40.
[0127] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:72. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:73. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:72, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:73. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:9, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:41, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:42, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:43.
[0128] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:74. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:75. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:74, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:75. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:11, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:44, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:45.
[0129] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:76. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:77. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:76, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:77. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:14, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:47, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:48.
[0130] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:78. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:79. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:78, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:79. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:15, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:16, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:17, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:49, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:50, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:48.
[0131] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:80. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:81. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:80, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:81. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:18, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:19, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:20, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:49, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:51, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:48.
[0132] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:82. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:83. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:82, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:83. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:21, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:22, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:23, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:50, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:48.
[0133] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:84. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:85. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:84, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:85. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:24, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:25, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:26, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:52, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:53, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:54.
[0134] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:86. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:87. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:86, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:87. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:27, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:28, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:29, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:55, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:56, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:57.
[0135] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:88. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:89. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:88, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:89. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:30, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:32, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:58, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:59, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:60.
[0136] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:90. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:91. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:90, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:91. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:33, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:34, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:61, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:62.
[0137] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:92. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:93. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:92, and a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:93. Furthermore, in some such embodiments, the anti-ActRIIB antibody or its antigen-binding fragment further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:14, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:50, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:63.
[0138] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:65.
[0139] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:67.
[0140] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:68, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:69.
[0141] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:71.
[0142] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:72, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:73.
[0143] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:74, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:75.
[0144] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:76, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:77.
[0145] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:78, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:79.
[0146] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:80, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:81.
[0147] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:82, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:83.
[0148] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:84, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:85.
[0149] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:86, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:87.
[0150] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:88, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:89.
[0151] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:90, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:91.
[0152] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:92, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:93.
[0153] In this disclosure, the antigen-binding fragment is a Fab fragment, an F(ab')2 fragment, an Fd fragment, an Fv fragment, a separated CDR region, or a scFv. In this disclosure, the anti-ActRIIB antibody or its antigen-binding fragment is fully human.
[0154] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment of the present disclosure may further comprise a constant region of an immunoglobulin, or a fragment, analog, variant, or derivative of said constant region. In some embodiments, the constant region comprises a heavy chain constant region and a light chain constant region. In some embodiments, the heavy chain constant region is derived from the heavy chain of human immunoglobulins, such as IgG1, IgG2, IgG3, IgG4, or other classes of immunoglobulins. In some embodiments, the light chain constant region is derived from the light chain of human immunoglobulins, such as the κ or λ light chain of human immunoglobulins. In some embodiments, the anti-ActRIIB antibody is an IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments, the anti-GPC3 antibody is a human IgG1, IgG2, IgG3, or IgG4 isotype. In some embodiments, the constant region may comprise any modification of the present disclosure or known in the art, such as the insertion, deletion, substitution, or chemical modification of amino acids. In some embodiments, the C-terminal lysine residue of the heavy chain constant region may be present or absent. In some embodiments, the heavy chain constant region contains mutations that prolong the antibody's half-life. In some embodiments, the heavy chain constant region contains YTE mutations (M252Y, S254T, and T256E according to EU designations). In some embodiments, the constant region contains mutations that alter effector function (such as ADCC and / or CDC). In some embodiments, the heavy chain constant region contains LALA mutations (L234A and L235A according to EU designations). In some embodiments, the heavy chain constant region contains P329A or P329G mutations (according to EU designations). In some embodiments, the heavy chain constant region contains LALAPA mutations (L234A, L235A, and P329A according to EU designations). In some embodiments, the heavy chain constant region contains LALAPG mutations (L234A, L235A, and P329G according to EU designations). In some embodiments, any amino acid residue in the constant region can be substituted with any allotype amino acid residue.
[0155] In some specific embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 94, 98, 102, 106, 110, 114, 118, 122, 126, 130, 134, 138, 142, 144, 148, or 152.
[0156] In some specific embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 146, 150, or 154.
[0157] In some specific embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 94, 98, 102, 106, 110, 114, 118, 122, 126, 130, 134, 138, 142, 144, 148, or 152, and an amino acid sequence identical to SEQ ID NO: 94, 98, 102, 106, 110, 114, 118, 122, 126, 130, 134, 138, 142, 144, 148, or 152. The amino acid sequence shown in NO:96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 146, 150 or 154 has a light chain with at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity.
[0158] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:94. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:96. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:94, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:96. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:2, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:35, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:36, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:37.
[0159] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 98. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 100. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 98, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO: 100. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:4, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:6, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:35, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:38, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:39.
[0160] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:102. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:104. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:102, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:104. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:3, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:35, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:36, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:40.
[0161] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:106. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:108. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:106, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:108. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:1, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:5, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:7, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:35, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:36, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:40.
[0162] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:110. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:112. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:110, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:112. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:9, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:41, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:42, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:43.
[0163] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:114. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:116. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:114, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:116. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:8, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:11, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:10, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:44, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:42, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:45.
[0164] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:118. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:120. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:118, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:120. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:14, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:47, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:48.
[0165] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:122. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:124. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:122, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:124. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:15, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:16, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:17, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:49, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:50, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:48.
[0166] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:126. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:128. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:126, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:128. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:18, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:19, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:20, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:49, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:51, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:48.
[0167] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:130. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:132. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:130, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:132. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:21, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:22, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:23, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:50, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:48.
[0168] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:134. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:136. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:134, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:136. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:24, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:25, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:26, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:52, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:53, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:54.
[0169] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:138. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:140. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:138, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:140. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:27, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:28, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:29, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:55, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:56, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:57.
[0170] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:142. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:146. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:142, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:146. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:30, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:32, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:58, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:59, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:60.
[0171] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:144. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:146. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:144, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:146. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:30, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:32, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:58, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:59, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:60.
[0172] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:148. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:150. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:148, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:150. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:33, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:34, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:61, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:62.
[0173] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:152. In some embodiments, the anti-ActRIIB antibody comprises a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO:154. In some embodiments, the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:152, and a light chain having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequence shown in SEQ ID NO:154. Furthermore, in some such embodiments, the anti-ActRIIB antibody further comprises: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:12, HCDR2 comprising the amino acid sequence shown in SEQ ID NO:13, HCDR3 comprising the amino acid sequence shown in SEQ ID NO:14, LCDR1 comprising the amino acid sequence shown in SEQ ID NO:46, LCDR2 comprising the amino acid sequence shown in SEQ ID NO:50, and LCDR3 comprising the amino acid sequence shown in SEQ ID NO:63.
[0174] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:94, and a light chain comprising the amino acid sequence shown in SEQ ID NO:96.
[0175] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:98, and a light chain comprising the amino acid sequence shown in SEQ ID NO:100.
[0176] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:102, and a light chain comprising the amino acid sequence shown in SEQ ID NO:104.
[0177] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:106, and a light chain comprising the amino acid sequence shown in SEQ ID NO:108.
[0178] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:110, and a light chain comprising the amino acid sequence shown in SEQ ID NO:112.
[0179] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:114, and a light chain comprising the amino acid sequence shown in SEQ ID NO:116.
[0180] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:118, and a light chain comprising the amino acid sequence shown in SEQ ID NO:120.
[0181] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:122, and a light chain comprising the amino acid sequence shown in SEQ ID NO:124.
[0182] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:126, and a light chain comprising the amino acid sequence shown in SEQ ID NO:128.
[0183] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:130, and a light chain comprising the amino acid sequence shown in SEQ ID NO:132.
[0184] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:134, and a light chain comprising the amino acid sequence shown in SEQ ID NO:136.
[0185] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:138, and a light chain comprising the amino acid sequence shown in SEQ ID NO:140.
[0186] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:142, and a light chain comprising the amino acid sequence shown in SEQ ID NO:146.
[0187] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:144, and a light chain comprising the amino acid sequence shown in SEQ ID NO:146.
[0188] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:148, and a light chain comprising the amino acid sequence shown in SEQ ID NO:150.
[0189] In some embodiments, the anti-ActRIIB antibody comprises: a heavy chain comprising the amino acid sequence shown in SEQ ID NO:152, and a light chain comprising the amino acid sequence shown in SEQ ID NO:154.
[0190] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:94 and a light chain of the amino acid sequence shown in SEQ ID NO:96.
[0191] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:98 and a light chain of the amino acid sequence shown in SEQ ID NO:100.
[0192] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:102 and a light chain of the amino acid sequence shown in SEQ ID NO:104.
[0193] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:106 and a light chain of the amino acid sequence shown in SEQ ID NO:108.
[0194] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:110 and a light chain of the amino acid sequence shown in SEQ ID NO:112.
[0195] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:114 and a light chain of the amino acid sequence shown in SEQ ID NO:116.
[0196] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:118 and a light chain of the amino acid sequence shown in SEQ ID NO:120.
[0197] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:122 and a light chain of the amino acid sequence shown in SEQ ID NO:124.
[0198] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:126 and a light chain of the amino acid sequence shown in SEQ ID NO:128.
[0199] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:130 and a light chain of the amino acid sequence shown in SEQ ID NO:132.
[0200] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:134 and a light chain of the amino acid sequence shown in SEQ ID NO:136.
[0201] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:138 and a light chain of the amino acid sequence shown in SEQ ID NO:140.
[0202] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:142 and a light chain of the amino acid sequence shown in SEQ ID NO:146.
[0203] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:144 and a light chain of the amino acid sequence shown in SEQ ID NO:146.
[0204] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:148 and a light chain of the amino acid sequence shown in SEQ ID NO:150.
[0205] In some embodiments, the anti-ActRIIB antibody comprises a heavy chain of the amino acid sequence shown in SEQ ID NO:152 and a light chain of the amino acid sequence shown in SEQ ID NO:154.
[0206] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:94, and the amino acid sequence of the light chain is shown in SEQ ID NO:96.
[0207] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:98, and the amino acid sequence of the light chain is shown in SEQ ID NO:100.
[0208] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:102, and the amino acid sequence of the light chain is shown in SEQ ID NO:104.
[0209] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:106, and the amino acid sequence of the light chain is shown in SEQ ID NO:108.
[0210] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:110, and the amino acid sequence of the light chain is shown in SEQ ID NO:112.
[0211] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:114, and the amino acid sequence of the light chain is shown in SEQ ID NO:116.
[0212] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:118, and the amino acid sequence of the light chain is shown in SEQ ID NO:120.
[0213] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:122, and the amino acid sequence of the light chain is shown in SEQ ID NO:124.
[0214] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:126, and the amino acid sequence of the light chain is shown in SEQ ID NO:128.
[0215] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:130, and the amino acid sequence of the light chain is shown in SEQ ID NO:132.
[0216] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:134, and the amino acid sequence of the light chain is shown in SEQ ID NO:136.
[0217] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:138, and the amino acid sequence of the light chain is shown in SEQ ID NO:140.
[0218] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:142, and the amino acid sequence of the light chain is shown in SEQ ID NO:146.
[0219] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:144, and the amino acid sequence of the light chain is shown in SEQ ID NO:146.
[0220] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:148, and the amino acid sequence of the light chain is shown in SEQ ID NO:150.
[0221] In some embodiments, the amino acid sequence of the heavy chain of the anti-ActRIIB antibody is shown in SEQ ID NO:152, and the amino acid sequence of the light chain is shown in SEQ ID NO:154.
[0222] It should be understood that the anti-ActRIIB antibodies involved here also include anti-ActRIIB antibodies with the heavy chain C-terminal lysine deficiency.
[0223] Tables S1 and S2 provide amino acid sequence information for the CDR and variable regions of some exemplary anti-ActRIIB antibodies or their antigen-binding fragments (e.g., S28, S31, S32, S36, S44, S51, S126, S127, S132, S144, S148, S150, S151, S151-YTE, S162, S163).
[0224] Table S1. Amino acid sequences of CDR and variable regions (SEQ ID NO:)
[0225] The anti-ActRIIB antibody or its antigen-binding fragment disclosed herein possesses good antigen-binding activity. Any of the anti-ActRIIB antibody or its antigen-binding fragment disclosed herein can bind to human ActRIIB. In some embodiments, any of the anti-ActRIIB antibody or its antigen-binding fragment disclosed herein can be measured using surface plasmon resonance (SPR) technology, as described below. D Combined with human ActRIIB: 1.00E-08M or less, 9.00E-09M or less, 8.00E-09M or less, 7.00E-09M or less, 6.56E-09M or less, 6.00E-09M or less, 5.00E-09M or less, 4.00E-09M or less, 3.84E-09M or less, 3.00E-09M or less, 2.11E-09M or less, 2.00E-09M or less, 1.57E-09M or less, 1.39E-09M or less, 1. 34E-09M or smaller, 1.16E-09M or smaller, 1.12E-09M or smaller, 1.11E-09M or smaller, 1.06E-09M or smaller, 1.03E-09M or smaller, 1.00E-09M or smaller, 9.31E-10M or smaller, 9.00E-10M or smaller, 8.72E-10M or smaller, 8.00E-10M or smaller, 7.41E-10M or smaller, 7.00E-10M or smaller, 6.00E-10M or smaller, or 5.63E-10M or smaller.
[0226] The anti-ActRIIB antibody or its antigen-binding fragment provided in this disclosure does not bind or substantially does not bind to human ActRIIA.
[0227] The anti-ActRIIB antibody or its antigen-binding fragment provided in this disclosure competitively binds to human ActRIIB with Activin A, GDF8 and / or GDF11.
[0228] The anti-ActRIIB antibody or its antigen-binding fragment provided in this disclosure can promote muscle formation.
[0229] The anti-ActRIIB antibody or its antigen-binding fragment provided in this disclosure can reduce fat formation.
[0230] The anti-ActRIIB antibody or its antigen-binding fragment provided in this disclosure can induce tumor growth and regression in vivo. In some embodiments, the tumor is a tumor expressing ActRIIB.
[0231] The anti-ActRIIB antibody or its antigen-binding fragment provided in this disclosure can delay tumor growth in vivo. In some embodiments, the tumor is a tumor expressing ActRIIB.
[0232] The anti-ActRIIB antibody or its antigen-binding fragment provided in this disclosure has good safety.
[0233] In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment is a monoclonal antibody. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment is a monospecific antibody. In some embodiments, the anti-ActRIIB antibody or its antigen-binding fragment is a multispecific antibody (e.g., a bispecific antibody, a trispecific antibody, etc.).
[0234] isolated nucleic acids
[0235] This disclosure provides isolated nucleic acids containing nucleotide sequences encoding the anti-ActRIIB antibody or its antigen-binding fragment as described in this disclosure. The sequence listing provides exemplary examples of nucleotide sequences encoding anti-ActRIIB antibodies or their antigen-binding fragments.
[0236] carrier
[0237] This disclosure provides vectors comprising the described nucleic acids. In some embodiments, the vector is a cloning vector. In other embodiments, the vector is an expression vector. As a specific example, the expression vector is pcDNA3.1(+). The expression vector may optionally be capable of expressing any expression vector of the anti-ActRIIB antibody or its antigen-binding fragment described in this disclosure.
[0238] host cells
[0239] This disclosure provides host cells comprising the nucleic acids or vectors of this disclosure. In some embodiments, the host cell is a suitable host cell for cloning or expressing an anti-ActRIIB antibody or its antigen-binding fragment. In some embodiments, the host cell is a prokaryotic cell. In other embodiments, the host cell is a eukaryotic cell. In some embodiments, the host cell is selected from yeast cells, mammalian cells, or other cells suitable for preparing an anti-ActRIIB antibody or its antigen-binding fragment. Mammalian cells include, for example, Chinese hamster ovary (CHO) cells and CHO-S cells.
[0240] Fusion protein
[0241] This disclosure provides a fusion protein comprising the anti-ActRIIB antibody of this disclosure or its antigen-binding fragment.
[0242] Antibody-drug conjugates (ADCs)
[0243] This disclosure provides antibody-drug conjugates comprising the anti-ActRIIB antibody of this disclosure or its antigen-binding fragment thereof. In some embodiments, the antibody-drug conjugate comprises the anti-ActRIIB antibody or its antigen-binding fragment thereof, and a cytotoxic drug.
[0244] Chimeric antigen receptor (CAR)
[0245] This disclosure also provides an anti-ActRIIB chimeric antigen receptor (CAR) comprising the anti-ActRIIB antibody of this disclosure or its antigen-binding fragment.
[0246] Anti-ActRIIB CARs may include (a) an extracellular antigen-binding domain containing ActRIIB binding; (b) a transmembrane domain; and (c) an intracellular signal transduction domain.
[0247] This disclosure also provides engineered immune effector cells that contain the CAR of this disclosure. In some embodiments, the immune effector cells are T cells, NK cells, peripheral blood mononuclear cells (PBMCs), hematopoietic stem cells, pluripotent stem cells, or embryonic stem cells.
[0248] Pharmaceutical Composition
[0249] This disclosure provides pharmaceutical compositions comprising an anti-ActRIIB antibody of this disclosure or an antigen-binding fragment thereof, a fusion protein, an antibody-drug conjugate, or engineered immune effector cells. In some embodiments, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients include, for example, excipients, diluents, encapsulating materials, fillers, buffers, or other reagents.
[0250] Methods for preparing anti-ActRIIB antibodies or their antigen-binding fragments
[0251] In some embodiments, this disclosure provides a method for preparing an anti-ActRIIB antibody or its antigen-binding fragment thereof, the method comprising: culturing the host cells to express the anti-ActRIIB antibody or its antigen-binding fragment, and isolating and purifying the anti-ActRIIB antibody or its antigen-binding fragment in the system. To generate the anti-ActRIIB antibody or its antigen-binding fragment, a nucleic acid encoding the anti-ActRIIB antibody or its antigen-binding fragment is isolated and inserted into one or more vectors for further cloning and / or expression in host cells. The nucleic acid can be obtained using various methods well known in the art, such as gene splicing and chemical synthesis.
[0252] The purity of anti-ActRIIB antibodies or their antigen-binding fragments can be determined using any of a variety of well-known analytical methods, such as gel electrophoresis, high-performance liquid chromatography, size exclusion chromatography, etc.
[0253] The physicochemical properties and / or biological activities of the anti-ActRIIB antibody or its antigen-binding fragment disclosed herein can be identified, screened, or characterized by a variety of assay methods known in the art.
[0254] use
[0255] This disclosure provides the use of the anti-ActRIIB antibody or its antigen-binding fragment thereof. In some specific embodiments, the anti-ActRIIB antibody used may be S28, S31, S32, S36, S44, S51, S126, S127, S132, S144, S148, S150, S151, S151-YTE, S162 and / or S163.
[0256] This disclosure provides the use of the anti-ActRIIB antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate, the engineered immune effector cells, or the pharmaceutical composition in the preparation of a medicament for treating diseases associated with ActRII expression or ActRII signaling. In some embodiments, this disclosure also provides the use of the anti-ActRIIB antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate, the engineered immune effector cells, or the pharmaceutical composition in the preparation of a medicament for use in combination with one or more additional therapeutic agents to treat diseases associated with ActRII expression or ActRII signaling.
[0257] This disclosure provides a method for treating diseases associated with ActRII expression or ActRII signaling, comprising administering to a subject the anti-ActRIIB antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate, the engineered immune effector cells, or the pharmaceutical composition. In some embodiments, the method involves administering to a subject a therapeutically effective amount of the anti-ActRIIB antibody or its antigen-binding fragment, the fusion protein, the antibody-drug conjugate, the engineered immune effector cells, or the pharmaceutical composition to treat diseases associated with ActRII expression or ActRII signaling. In some embodiments, the method includes further administering to the subject one or more additional therapeutic agents.
[0258] In some embodiments, in the above uses and methods, the disease is a musculoskeletal system disease, an endocrine and metabolic system disease, an immune system disease, a blood disease, a cardiovascular system disease, a fibrotic disease, and / or a tumor. In some embodiments, in the above uses and methods, the disease is myositis, sarcopenia, muscle atrophy, muscular dystrophy, muscle loss, osteoporosis, bone loss, diabetes, obesity, non-alcoholic steatohepatitis, cirrhosis, autoimmune diseases, anemia, pulmonary hypertension, heart failure, liver fibrosis, pulmonary fibrosis, renal fibrosis, vascular fibrosis, and / or a tumor.
[0259] In some embodiments, in the above uses and methods, the disease is an age-related condition. In some embodiments, the age-related condition is sarcopenia, skin atrophy, muscle wasting, brain atrophy, atherosclerosis, arteriosclerosis, emphysema, osteoporosis, osteoarthritis, immunodeficiency, hypertension, dementia, Huntington's disease, Alzheimer's disease, cataracts, age-related macular degeneration, prostate cancer, stroke, shortened life expectancy, frailty, memory loss, wrinkles, impaired kidney function, and / or age-related hearing loss.
[0260] Reagent test kit
[0261] This disclosure provides a kit comprising the anti-ActRIIB antibody or its antigen-binding fragment thereof, a fusion protein, an antibody-drug conjugate, engineered immune effector cells, or a pharmaceutical composition of this disclosure. In some embodiments, the kit may be used for purposes such as implementing the anti-ActRIIB antibody or its antigen-binding fragment thereof, fusion protein, antibody-drug conjugate, engineered immune effector cells, or pharmaceutical composition provided by this disclosure, or for other purposes. In some embodiments, the kit may include the anti-ActRIIB antibody or its antigen-binding fragment thereof, fusion protein, antibody-drug conjugate, engineered immune effector cells, or pharmaceutical composition of this disclosure, and reagents for detecting the presence of ActRIIB in a biological sample. The kit may also include instructions for use. The kit may also include other materials required from a commercial and user perspective, such as other buffers, diluents, needles, syringes, etc. Detailed Implementation
[0262] This disclosure also provides the following specific implementation schemes, but the scope of protection of this disclosure is not limited thereto:
[0263] Implementation Scheme 1. An anti-ActRIIB antibody or its antigen-binding fragment, comprising: HCDR1 comprising the amino acid sequence shown in SEQ ID NO: 1, 4, 8, 12, 15, 18, 21, 24, 27 or 30; HCDR2 comprising the amino acid sequence shown in SEQ ID NO: 2, 5, 9, 11, 13, 16, 19, 22, 25, 28, 31 or 33; HCDR3 comprising the amino acid sequence shown in SEQ ID NO: 3, 6, 7, 10, 14, 17, 20, 23, 26, 29, 32 or 34; LCDR1 comprising the amino acid sequence shown in SEQ ID NO: 35, 41, 44, 46, 49, 52, 55 or 58; LCDR2 comprising the amino acid sequence shown in SEQ ID NO: 36, 38, 42, 47, 50, 51, 53, 56, 59 or 61; and comprising SEQ ID NO: 1, 4, 8, 12, 15, 18, 21, 24, 27 or 30; LCDR3 with amino acid sequences shown in NO:37, 39, 40, 43, 45, 48, 54, 57, 60, 62 or 63.
[0264] Implementation Scheme 2. The anti-ActRIIB antibody or its antigen-binding fragment according to Implementation Scheme 1, wherein the anti-ActRIIB antibody or its antigen-binding fragment comprises:
[0265] (1) HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:2, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:37.
[0266] (2) HCDR1 containing the amino acid sequence shown in SEQ ID NO:4, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:6, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:38, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:39.
[0267] (3) HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40.
[0268] (4) HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:7, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:40.
[0269] (5) HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:9, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:41, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:43.
[0270] (6) HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:11, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:44, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:45.
[0271] (7) HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:47, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48.
[0272] (8) HCDR1 containing the amino acid sequence shown in SEQ ID NO:15, HCDR2 containing the amino acid sequence shown in SEQ ID NO:16, HCDR3 containing the amino acid sequence shown in SEQ ID NO:17, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48.
[0273] (9) HCDR1 containing the amino acid sequence shown in SEQ ID NO:18, HCDR2 containing the amino acid sequence shown in SEQ ID NO:19, HCDR3 containing the amino acid sequence shown in SEQ ID NO:20, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:51, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48.
[0274] (10) HCDR1 containing the amino acid sequence shown in SEQ ID NO:21, HCDR2 containing the amino acid sequence shown in SEQ ID NO:22, HCDR3 containing the amino acid sequence shown in SEQ ID NO:23, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:48.
[0275] (11) HCDR1 containing the amino acid sequence shown in SEQ ID NO:24, HCDR2 containing the amino acid sequence shown in SEQ ID NO:25, HCDR3 containing the amino acid sequence shown in SEQ ID NO:26, LCDR1 containing the amino acid sequence shown in SEQ ID NO:52, LCDR2 containing the amino acid sequence shown in SEQ ID NO:53, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:54.
[0276] (12) HCDR1 containing the amino acid sequence shown in SEQ ID NO:27, HCDR2 containing the amino acid sequence shown in SEQ ID NO:28, HCDR3 containing the amino acid sequence shown in SEQ ID NO:29, LCDR1 containing the amino acid sequence shown in SEQ ID NO:55, LCDR2 containing the amino acid sequence shown in SEQ ID NO:56, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:57.
[0277] (13) HCDR1 containing the amino acid sequence shown in SEQ ID NO:30, HCDR2 containing the amino acid sequence shown in SEQ ID NO:31, HCDR3 containing the amino acid sequence shown in SEQ ID NO:32, LCDR1 containing the amino acid sequence shown in SEQ ID NO:58, LCDR2 containing the amino acid sequence shown in SEQ ID NO:59, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:60.
[0278] (14) HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:33, HCDR3 containing the amino acid sequence shown in SEQ ID NO:34, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:61, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:62; or
[0279] (15) HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:63.
[0280] Implementation Scheme 3. An anti-ActRIIB antibody or an antigen-binding fragment thereof, comprising: HCDR1, HCDR2, and HCDR3 in a heavy chain variable region as shown in SEQ ID NO: 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, or 92, and LCDR1, LCDR2, and LCDR3 in a light chain variable region as shown in SEQ ID NO: 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, or 93, wherein the CDRs are defined according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
[0281] Implementation Scheme 4. The anti-ActRIIB antibody or its antigen-binding fragment according to Implementation Scheme 3, wherein the anti-ActRIIB antibody or its antigen-binding fragment comprises:
[0282] (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:65;
[0283] (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:66, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:67;
[0284] (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:68, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:69;
[0285] (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:70, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:71;
[0286] (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:72, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:73;
[0287] (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:74, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:75;
[0288] (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:76, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:77.
[0289] (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:78, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:79;
[0290] (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:80, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:81;
[0291] (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:82, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:83;
[0292] (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:84, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:85;
[0293] (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:86, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:87.
[0294] (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:88, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:89;
[0295] (14) HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:90, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:91; or
[0296] (15) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:92, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:93;
[0297] The CDR is defined according to Kabat, IMGT, Chothia, Contact, AbM and / or CCG.
[0298] Implementation Scheme 5. An anti-ActRIIB antibody or antigen-binding fragment thereof according to any one of Implementation Schemes 1-4, wherein the anti-ActRIIB antibody or antigen-binding fragment thereof comprises a heavy chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, or 92.
[0299] Implementation Scheme 6. An anti-ActRIIB antibody or antigen-binding fragment thereof according to any one of Implementation Schemes 1-5, wherein the anti-ActRIIB antibody or antigen-binding fragment thereof comprises a light chain variable region having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, or 93.
[0300] Implementation Scheme 7. An anti-ActRIIB antibody or an antigen-binding fragment thereof according to any one of Implementation Schemes 1-6, wherein the anti-ActRIIB antibody or the antigen-binding fragment thereof comprises:
[0301] (1) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:65;
[0302] (2) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:67;
[0303] (3) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:68, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:69;
[0304] (4) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:71;
[0305] (5) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:72, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:73;
[0306] (6) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:74, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:75;
[0307] (7) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:76, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:77;
[0308] (8) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:78, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:79;
[0309] (9) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:80, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:81;
[0310] (10) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:82, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:83;
[0311] (11) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:84, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:85;
[0312] (12) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:86, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:87;
[0313] (13) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:88, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:89;
[0314] (14) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 90, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 91; or
[0315] (15) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:92, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:93.
[0316] Implementation Scheme 8. An anti-ActRIIB antibody or an antigen-binding fragment thereof according to any one of Implementation Schemes 1-7, wherein the anti-ActRIIB antibody or the antigen-binding fragment thereof comprises:
[0317] (1) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:64 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:65;
[0318] (2) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:67;
[0319] (3) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:68 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:69;
[0320] (4) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:71;
[0321] (5) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:72, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:73;
[0322] (6) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:74, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:75;
[0323] (7) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:76, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:77;
[0324] (8) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:78, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:79;
[0325] (9) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:80 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:81;
[0326] (10) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:82 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:83;
[0327] (11) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:84, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:85;
[0328] (12) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:86, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:87;
[0329] (13) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:88 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:89;
[0330] (14) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:90, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:91; or
[0331] (15) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:92 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:93.
[0332] Implementation Scheme 9. An anti-ActRIIB antibody or its antigen-binding fragment according to any one of Implementation Schemes 1-8, wherein the antigen-binding fragment is a Fab fragment, an F(ab')2 fragment, an Fd fragment, an Fv fragment, a separated CDR region, or a scFv.
[0333] Implementation Scheme 10. An anti-ActRIIB antibody or its antigen-binding fragment according to any one of Implementation Schemes 1-9, wherein the anti-ActRIIB antibody is an IgG1, IgG2, IgG3 or IgG4 isotype.
[0334] Implementation Scheme 11. An anti-ActRIIB antibody or an antigen-binding fragment thereof according to any one of Implementation Schemes 1-10, wherein the anti-ActRIIB antibody comprises a heavy chain having an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 94, 98, 102, 106, 110, 114, 118, 122, 126, 130, 134, 138, 142, 144, 148, or 152.
[0335] Implementation Scheme 12. An anti-ActRIIB antibody or an antigen-binding fragment thereof according to any one of Implementation Schemes 1-11, wherein the anti-ActRIIB antibody comprises a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 146, 150, or 154.
[0336] Implementation Scheme 13. An anti-ActRIIB antibody or an antigen-binding fragment thereof according to any one of Implementation Schemes 1-12, wherein the anti-ActRIIB antibody comprises:
[0337] (1) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:94, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:96;
[0338] (2) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 98, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 100;
[0339] (3) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:102, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:104;
[0340] (4) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:106, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:108;
[0341] (5) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:110, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:112;
[0342] (6) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:114, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:116;
[0343] (7) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:118, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:120;
[0344] (8) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:122, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:124;
[0345] (9) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:126, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:128;
[0346] (10) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:130, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:132;
[0347] (11) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:134, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:136;
[0348] (12) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:138, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:140;
[0349] (13) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:142, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:146;
[0350] (14) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:144, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:146;
[0351] (15) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:148, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:150; or
[0352] (16) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:152, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:154.
[0353] Implementation Scheme 14. An anti-ActRIIB antibody or an antigen-binding fragment thereof, wherein the anti-ActRIIB antibody comprises:
[0354] (1) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:94, and a light chain comprising the amino acid sequence shown in SEQ ID NO:96;
[0355] (2) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:98, and a light chain comprising the amino acid sequence shown in SEQ ID NO:100;
[0356] (3) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:102, and a light chain comprising the amino acid sequence shown in SEQ ID NO:104;
[0357] (4) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:106, and a light chain comprising the amino acid sequence shown in SEQ ID NO:108;
[0358] (5) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:110, and a light chain comprising the amino acid sequence shown in SEQ ID NO:112;
[0359] (6) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:114, and a light chain comprising the amino acid sequence shown in SEQ ID NO:116;
[0360] (7) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:118, and a light chain comprising the amino acid sequence shown in SEQ ID NO:120;
[0361] (8) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:122, and a light chain comprising the amino acid sequence shown in SEQ ID NO:124;
[0362] (9) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:126, and a light chain comprising the amino acid sequence shown in SEQ ID NO:128;
[0363] (10) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:130, and a light chain comprising the amino acid sequence shown in SEQ ID NO:132;
[0364] (11) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:134, and a light chain comprising the amino acid sequence shown in SEQ ID NO:136;
[0365] (12) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:138, and a light chain comprising the amino acid sequence shown in SEQ ID NO:140;
[0366] (13) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:142, and a light chain comprising the amino acid sequence shown in SEQ ID NO:146;
[0367] (14) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:144, and a light chain comprising the amino acid sequence shown in SEQ ID NO:146;
[0368] (15) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:148 and a light chain comprising the amino acid sequence shown in SEQ ID NO:150; or (16) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:152 and a light chain comprising the amino acid sequence shown in SEQ ID NO:154.
[0369] Implementation Scheme 15. An anti-ActRIIB antibody or its antigen-binding fragment according to any one of Implementation Schemes 1-14, wherein the anti-ActRIIB antibody or its antigen-binding fragment has one or more of the following properties:
[0370] (1) Combined with human ActRIIB; preferably, measured by surface plasmon resonance technology, with K D For 1.00E-08M or less, 9.00E-09M or less, 8.00E-09M or less, or 7.00E-09M or less, the combination of human ActRIIB;
[0371] (2) ActRIIA (non-conjugated or largely non-conjugated persons);
[0372] (3) Competing with ActivinA, GDF8 and / or GDF11 to bind to human ActRIIB;
[0373] (4) Promotes muscle formation;
[0374] (5) Reduce fat formation;
[0375] (6) Induces tumor growth and regression in vivo; and
[0376] (7) Delay the growth of tumors in the body.
[0377] Implementation Scheme 16. An isolated nucleic acid comprising a nucleotide sequence encoding an anti-ActRIIB antibody or an antigen-binding fragment thereof as described in any one of Implementation Schemes 1-15.
[0378] Implementation Scheme 17. A vector comprising the nucleic acid described in Implementation Scheme 16.
[0379] Implementation Scheme 18. A host cell comprising the nucleic acid described in Implementation Scheme 16, or the vector described in Implementation Scheme 17.
[0380] Implementation Scheme 19. A method for preparing an anti-ActRIIB antibody or an antigen-binding fragment thereof as described in any one of Implementation Schemes 1-15, comprising culturing the host cells described in Implementation Scheme 18 to express the anti-ActRIIB antibody or the antigen-binding fragment thereof, and isolating and purifying the anti-ActRIIB antibody or the antigen-binding fragment thereof in the system.
[0381] Implementation Scheme 20. A fusion protein comprising any one of the anti-ActRIIB antibodies or antigen-binding fragments thereof described in Implementation Schemes 1-15.
[0382] Implementation Scheme 21. An antibody-drug conjugate comprising any one of the anti-ActRIIB antibodies or antigen-binding fragments thereof described in Implementation Schemes 1-15.
[0383] Implementation Scheme 22. A chimeric antigen receptor comprising any one of the anti-ActRIIB antibodies or antigen-binding fragments thereof described in Implementation Schemes 1-15.
[0384] Implementation Scheme 23. An engineered immune effector cell comprising the chimeric antigen receptor described in Implementation Scheme 22.
[0385] Implementation Scheme 24. A pharmaceutical composition comprising an anti-ActRIIB antibody or an antigen-binding fragment thereof according to any one of Implementation Schemes 1-15, a fusion protein according to Implementation Scheme 20, an antibody-drug conjugate according to Implementation Scheme 21, or an engineered immune effector cell according to Implementation Scheme 23; optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
[0386] Implementation Scheme 25. Use of any anti-ActRIIB antibody or antigen-binding fragment thereof according to any one of Implementation Schemes 1-15, the fusion protein of Implementation Scheme 20, the antibody-drug conjugate of Implementation Scheme 21, the engineered immune effector cells of Implementation Scheme 23, or the pharmaceutical composition of Implementation Scheme 24 in the preparation of a medicament for treating diseases related to ActRII expression or ActRII signaling.
[0387] Implementation Scheme 26. The use according to Implementation Scheme 25, wherein the disease is a musculoskeletal system disease, an endocrine and metabolic system disease, an immune system disease, a blood disease, a cardiovascular system disease, a fibrotic disease, and / or a tumor.
[0388] Implementation Scheme 27. The use according to Implementation Scheme 25 or 26, wherein the disease is myositis, sarcopenia, muscle atrophy, muscular dystrophy, muscle loss, osteoporosis, bone loss, diabetes, obesity, non-alcoholic steatohepatitis, cirrhosis, autoimmune diseases, anemia, pulmonary hypertension, heart failure, liver fibrosis, pulmonary fibrosis, renal fibrosis, vascular fibrosis and / or tumors.
[0389] Implementation Scheme 28. A method for treating diseases associated with ActRII expression or ActRII signaling, comprising administering to a subject an anti-ActRIIB antibody or an antigen-binding fragment thereof as described in any one of Implementation Schemes 1-15, a fusion protein as described in Implementation Scheme 20, an antibody-drug conjugate as described in Implementation Scheme 21, engineered immune effector cells as described in Implementation Scheme 23, or a pharmaceutical composition as described in Implementation Scheme 24.
[0390] Implementation Scheme 29. The method according to Implementation Scheme 28, wherein the disease is a musculoskeletal system disease, an endocrine and metabolic system disease, an immune system disease, a blood disease, a cardiovascular system disease, a fibrotic disease, and / or a tumor.
[0391] Implementation Scheme 30. The method according to Implementation Scheme 28 or 29, wherein the disease is myositis, sarcopenia, muscle atrophy, muscular dystrophy, muscle loss, osteoporosis, bone loss, diabetes, obesity, non-alcoholic steatohepatitis, cirrhosis, autoimmune diseases, anemia, pulmonary hypertension, heart failure, liver fibrosis, pulmonary fibrosis, renal fibrosis, vascular fibrosis and / or tumors.
[0392] Implementation Scheme 31. A kit comprising the anti-ActRIIB antibody or its antigen-binding fragment as described in any one of Implementation Schemes 1-15, the fusion protein as described in Implementation Scheme 20, the antibody-drug conjugate as described in Implementation Scheme 21, the engineered immune effector cells as described in Implementation Scheme 23, or the pharmaceutical composition as described in Implementation Scheme 24.
[0393] For clarity, this disclosure is further illustrated by embodiments, but these embodiments are not intended to limit the scope of this disclosure. Those skilled in the art will readily identify various non-critical parameters that can be changed or modified to produce substantially similar results.
[0394] All reagents used in the examples, unless otherwise stated, are commercially available.
[0395] In specific embodiments of this disclosure, Bimagrumab (BM1), Fc-modified Bimagrumab (BM1-YTE), and LA01 (BM2) are used as positive references. LA01 VH and VL are the sequences shown in SEQ ID NO:12 and SEQ ID NO:38 of WO2023030503A1, respectively. In this disclosure, the amino acid sequences of Bimagrumab VH and VL are shown in SEQ ID NO:158 and SEQ ID NO:159, respectively; the amino acid sequences of the heavy and light chains of Bimagrumab are shown in SEQ ID NO:160 and SEQ ID NO:161, respectively; and the amino acid sequences of LA01 VH and VL are shown in SEQ ID NO:162 and SEQ ID NO:163, respectively.
[0396] Bimagrumab heavy and light chain gene synthesis fragments were cloned into the expression vector pcDNA3.1(+) (Invitrogen, catalog number: V-79020), transfected into ExpiCHO cells for transient expression, and purified using a protein A column (GE HealthCare) to obtain BM1. Bimagrumab VH gene synthesis fragments were cloned into the expression vector pcDNA3.1(+) containing the human IgG1 heavy chain constant region modified with L234A, L235A, P329A, M252Y, S254T, and T256E, respectively. The Bimagrumab light chain gene synthesis fragment was cloned into the expression vector pcDNA3.1(+), transfected into ExpiCHO cells for expression, and purified to obtain BM1-YTE. The VH and VL gene fragments of LA01 were cloned into pcDNA3.1(+) expression vectors containing the human IgG1 heavy chain constant region and the human κ light chain constant region modified by L234A and L235A, respectively. The vectors were then transfected into ExpiCHO cells for expression and purified to obtain BM2.
[0397] Example 1: Preparation of anti-ActRIIB monoclonal antibody
[0398] The open reading frame DNA sequences encoding the extracellular domains of human ActRIIA protein (Uniprot: P27037) and human ActRIIB protein (Uniprot: Q13705) were fused with human IgG1 Fc tag DNA sequences, respectively. The synthesized DNA sequences were subcloned into the expression vector pcDNA3.1(+) (Invitrogen, catalog number: V-79020), and the expression vector was transfected into Expi293 cells for transient expression. The fusion proteins ActRIIA-Fc Tag (SEQ ID NO: 156) and ActRIIB-Fc Tag (SEQ ID NO: 157) were obtained by purification using a protein A column (GE HealthCare).
[0399] ActRIIA-Fc Tag (50 μg / mouse) and ActRIIB-Fc Tag (50 μg / mouse) were mixed with an equal volume of immune adjuvant (Sigma, catalog number: T2684) (for the first immunization) and administered subcutaneously. Mice (Shanghai Iminocon Biotechnology Co., Ltd.) were immunized every 3 weeks for 12 weeks. Three days before fusion, a booster immunization was administered via intraperitoneal injection of adjuvant-free ActRIIB-Fc Tag (50 μg / mouse). Splenocytes (1 × 10⁻⁶ cells) from mice were fused using an electrofusion instrument (BTX, model: ECM2001). 8 (5 × 10) and SP2 / 0 myeloma cells (5 × 10) 7 Hybridoma cells were obtained by fusing cells with 1% HAT (Gibco, catalog number: 21060017) and 2% fetal bovine serum (Gibco, catalog number: 10099-141). After fusion, the cells were resuspended in 500 mL of SFM hybridoma medium (Gibco, catalog number: 12045-076) containing 1% HAT (Gibco, catalog number: 21060017) and 2% fetal bovine serum (Gibco, catalog number: 10099-141), and aliquoted at 0.1 mL / well into 96-well plates. The plates were then cultured at 37°C in a 5% CO2 incubator. Single clones capable of blocking the binding of ActRIIB to Activin A ligand were further screened using protein-based blocking activity screening and subcloning.
[0400] Example 2: Construction and expression of anti-ActRIIB antibody
[0401] Total RNA was isolated from selected monoclonal cells with blocking function using a total RNA extraction kit (Takara, catalog number: 9769) as a template, and first-strand cDNA was synthesized using superscript III reverse transcriptase (Vazyme, catalog number: R312-02). Then, using the first-strand cDNA as a template, the variable region sequence of the antibody was amplified by PCR using degenerate human IgG primers. The PCR product was sequenced to obtain the heavy chain variable region (VH) sequence and the light chain variable region (VL) sequence of the antibody. The VH region gene fragment of the anti-ActRIIB antibody was ligated into the human IgG1 heavy chain constant region modified by L234A, L235A, and P329A, or the human IgG1 heavy chain constant region modified by L234A, L235A, P329A, M252Y, S254T, and T256E to construct a heavy chain expression plasmid. The VL region gene fragment was ligated into the human κ light chain constant region to construct a light chain expression plasmid. These plasmids were cloned into the pcDNA3.1(+) expression vector, transfected into ExpiCHO cells for expression, and purified to obtain fully human anti-ActRIIB antibodies S28, S31, S32, S36, S44, S51, S126, S127, S132, S144, S148, S150, S151, S151-YTE, S162, and S163. The sequence information of the anti-ActRIIB antibodies is shown in Table 1 below.
[0402] Table 1. Sequence information of anti-ActRIIB antibodies (SEQ ID NO:)
[0403] Example 3: Determination of anti-ActRIIB antibody affinity
[0404] Anti-ActRIIB antibodies were captured using a CM5 biosensor (GE, catalog number: 29149603) conjugated with an anti-human IgG antibody (GE, catalog number: 29234600). The antibodies were then passed over either a human ActRIIA protein His Tag (Acro biosystems, catalog number: ACA-H5243) or a human ActRIIB protein His Tag (Acro biosystems, catalog number: ACB-H5226) on the chip surface. The reaction signal was detected in real-time using a Biacore 8K instrument. Data analysis was performed using Biacore Insight Evaluation Software 3.0, and the binding rate constant k was calculated by fitting the data to a Langmuir 1:1 model. a (1 / Ms), dissociation rate constant k d (1 / s), equilibrium dissociation constant K D(M) value. The results are shown in Table 2. The tested anti-ActRIIB antibodies have a high affinity for human ActRIIB protein, while S31, S44, S51, S126, S127, S132, S144, S150, S151, and S163 do not bind to human ActRIIB protein.
[0405] Table 2. Binding affinity of anti-ActRIIB antibodies to human ActRIIA or ActRIIB
[0406] Example 4: Protein-based binding analysis of anti-ActRIIB antibody
[0407] Add 0.1 μg / mL human ActRIIA protein His Tag (Acro biosystems, catalog number: ACA-H5243) or 1 μg / mL human ActRIIB protein His Tag (Acro biosystems, catalog number: ACB-H5226) to 96-well plates at 100 μL / well and coat overnight at 4°C. After coating, wash the plate three times with PBST buffer, add 150 μL / well of 1% BSA (Sigma, catalog number: B2064-100g) for blocking, and incubate at 37°C for 1 hour. After blocking, wash the plate three times with PBST buffer, add 100 μL of serially diluted (starting concentration 66.7 nM, 5-fold serial dilution 7 times) of anti-ActRIIB antibody, and incubate at 37°C for 1 hour. After incubation, wash the plate three times with PBST buffer. Add 100 μL of horseradish peroxidase (HRP)-conjugated goat anti-human IgG antibody (Jackson ImmunoResearch, catalog number: 109-035-098) diluted 1:2000 with PBS buffer to each well and incubate at 37°C for 30 minutes. After washing the plate three times with PBST buffer, add 100 μL of TMB chromogenic substrate (TIANGEN, catalog number: PA107-01) to each well. After developing for several minutes, add 50 μL of phosphate (10-fold diluted with ddH2O, catalog number: 10015418) to each well to stop the reaction. Measure the absorbance using a microplate reader (Tecan, model: Infinite F50, Switzerland) at a wavelength of 450 nm. Fit the antibody-antigen binding curve and calculate the EC50. 50 The results are shown in Figures 1A-1H and Table 3-10. S150 does not bind to ActRIIB, while S31, S44, S127, S132, and S151 have weak binding. The tested anti-ActRIIB antibodies have good binding activity with human ActRIIB.
[0408] Table 3. Binding of anti-ActRIIB antibody to human ActRIIA (EC)50
[0409] Table 4. Binding of anti-ActRIIB antibody to human ActRIIA (EC) 50
[0410] Table 5. Binding of anti-ActRIIB antibody to human ActRIIB (EC) 50
[0411] Table 6. Binding of anti-ActRIIB antibody to human ActRIIB (EC) 50
[0412] Table 7. Binding of anti-ActRIIB antibody to human ActRIIB (EC) 50
[0413] Table 8. Binding of anti-ActRIIB antibody to human ActRIIB (EC) 50
[0414] Table 9. Binding of anti-ActRIIB antibody to human ActRIIB (EC) 50
[0415] Table 10. Binding of anti-ActRIIB antibody to human ActRIIB (EC) 50
[0416] Example 5: Cell-based binding analysis of anti-ActRIIB antibodies
[0417] The full-length gene sequence encoding the human ActRIIA protein (Uniprot: P27037) was subcloned into the expression vector pcDNA3.1(+). The vector was transfected into CHO-K1 cells using Lipofectamine 3000 (Invitrogen, catalog number: L3000-015). After selection with G418 (Gibco, catalog number: 10131-027), ActRIIA-positive monoclonal cell lines were obtained by FACS detection and named CHO-K1-ActRIIA.
[0418] Resuspend CHO-K1-ActRIIA cells in FACS buffer (PBS + 2% FBS) to a cell density of 1×10⁻⁶ cells / cells. 6Cells were added at 100 μL / well to a 96-well plate, followed by 100 μL of serially diluted anti-ActRIIB antibody (starting concentration 66.7 nm, 7 three-fold dilutions) with PBS buffer to each well. The plates were incubated at 4°C in the dark for 1 hour. After incubation, the cells were centrifuged at 1000 rpm for 5 minutes, the supernatant was discarded, and the cells were washed three times with FACS buffer. Then, 100 μL / well of PE-mouse anti-human Fcγ antibody (Jackson ImmunoResearch, catalog number: 109-116-170) diluted 1:200 was added, and the plates were incubated at 4°C in the dark for 30 minutes. After washing the cells three times with FACS buffer, the mean fluorescence intensity (MFI) was measured using a Sartorius iQue3 flow cytometer to analyze the EC. 50 The results are shown in Figures 2A-2B, Tables 11 and 12. S150 does not bind to CHO-K1-ActRIIA, S151 has a weak binding, and other antibodies have good binding activity.
[0419] Table 11. Cell-based binding of anti-ActRIIB antibodies to EC 50
[0420] Table 12 Cell-based binding of anti-ActRIIB antibodies to EC 50
[0421] Example 6: Protein-based blocking analysis of anti-ActRIIB antibody
[0422] Add 1 μg / mL ActRIIA-Fc Tag (SEQ ID NO:156) or ActRIIB-Fc Tag (SEQ ID NO:157) to 96-well plates at 100 μL / well and coat overnight at 4°C. After coating, wash the plate three times with PBST buffer, add 1% BSA (Sigma, catalog number: B2064-100g) for blocking, and incubate at 37°C for 1 hour. After blocking, wash the plate three times with PBST buffer, add 50 μL of serially diluted (starting concentration 66.7 nM, 2-fold serial dilution 7 times) of anti-ActRIIB antibody, and incubate at 37°C for 1 hour. After incubation, add 50 μL of 0.1 μg / mL Activin A (E-Link NHS-PEG4-biotin (Thermo, catalog number: A39259) labeled with EZ-link NHS-PEG4-biotin (0429-HNAH) to each well, and incubate at 37°C for 1 hour. After washing the plate three times with PBST buffer, add 100 μL of horseradish peroxidase (HRP)-conjugated streptavidin (Jackson ImmunoResearch, catalog number: 016-030-084) diluted 1:2000 with PBS buffer to each well and incubate at 37°C for 30 minutes. Add 100 μL of TMB chromogenic substrate (TIANGEN, catalog number: PA107-01) to each well. After several minutes of development, add 50 μL of phosphate (Shanghai Pharmaceutical, catalog number: 10015418) diluted 10-fold with ddH2O to each well to stop the reaction. Measure the absorbance using a microplate reader (Tecan, model: Infinite F50, Switzerland) at a wavelength of 450 nm. Fit the antibody-antigen binding curve and calculate the IC50. 50 The results are shown in Figures 3A-3H, 4A-4H and Table 12-19. The tested anti-ActRIIB antibody showed good blocking activity against the binding of ActRIIB to Activin A, but no blocking activity against the binding of ActRIIA to Activin A.
[0423] Table 12 Anti-ActRIIB antibody protein-based blocking IC50 50
[0424] Table 13 Anti-ActRIIB antibody protein-based blocking IC50 50
[0425] Table 14. Anti-ActRIIB antibody protein-based blocking IC50 50
[0426] Table 15. Anti-ActRIIB antibody protein-based blocking IC5050
[0427] Table 16. Anti-ActRIIB antibody protein-based blocking IC50 50
[0428] Table 17 Anti-ActRIIB antibody protein-based blocking IC50 50
[0429] Table 18. Anti-ActRIIB antibody protein-based blocking IC50 50
[0430] Table 19 Anti-ActRIIB antibody protein-based blocking IC50 50
[0431] Example 7: Cell-based blocking analysis of anti-ActRIIB antibodies
[0432] H_ACVR2B Reporter Cell Line (Jiman Biotechnology, catalog number: GM-C26076) cells were resuspended in Opti-MEM (Gibco, catalog number: 31985070) for counting, and the cell density was adjusted to 1.5 × 10⁻⁶. 5 For Activin A blocking assay, the antibody was initially diluted 8 times (3-fold serial dilution) with Opti-MEM to 1.2 ng / mL, and 50 μL / well was added to each well of a 96-well plate and incubated at 37°C with 5% CO2 for 24 hours. For Activin A blocking assay, the antibody was initially diluted 8 times (3-fold serial dilution) with Opti-MEM to 1.2 ng / mL, and 50 μL / well was added to each well of a 96-well plate and incubated at 37°C with 5% CO2 for 60 minutes. For GDF8 blocking assays, except for S151-YTE, which was started at 400 nM and serially diluted 9 times with Opti-MEM in a 3-fold serial pattern, all other antibodies were started at 1000 nM and serially diluted 9 times with Opti-MEM in a 3-fold serial pattern. 50 μL / well was added to each well of a 96-well plate and incubated at 37°C in a 5% CO2 incubator for 60 minutes. GDF8 (R&D, catalog number: 788-G8-100 / CF) was diluted with Opti-MEM to 10 ng / mL, and 50 μL / well was added to each well of a 96-well plate and incubated at 37°C in a 5% CO2 incubator for 6 hours. 100 μL / well of Bio-Lite (Novizan, catalog number: DD1201) was added for chemiluminescence detection, and the IC50 was calculated. 50The results are shown in Figures 5A-5D, 6A-6D and Tables 20-23. The tested anti-ActRIIB antibodies showed good blocking activity against the binding of ActRIIB to Activin A or GDF8.
[0433] Table 20 Cell-based blocking IC50 of anti-ActRIIB antibodies 50
[0434] Table 21 Cell-based blocking IC50 of anti-ActRIIB antibodies 50
[0435] Table 22 Cell-based blocking IC50 of anti-ActRIIB antibodies 50
[0436] Table 23 Cell-based blocking IC50 of anti-ActRIIB antibodies 50
[0437] Example 8: Pharmacokinetics of anti-ActRIIB antibody in cynomolgus monkeys
[0438] The pharmacokinetic (PK) characteristics of BM1-YTE and S151-YTE were evaluated in cynomolgus monkeys, and the results are shown in Figure 7 and Table 24. After a single intravenous injection of BM1-YTE and S151-YTE at a dose of 10 mg / kg, the exposure of S151-YTE was higher than that of BM1-YTE, and the half-life was longer.
[0439] Table 24 Pharmacokinetic parameters of anti-ActRIIB antibody in cynomolgus monkeys
[0440] The sequence information disclosed herein is summarized in Table S2 below.
[0441] Table S2. Sequence Information
[0442] For purposes of description and disclosure, all patents, patent applications, and other identified publications are expressly incorporated herein by reference. These publications are provided solely because their publications predate the filing date of this disclosure. All statements regarding the dates of these documents or representations of their contents are based on information available to the applicant and do not constitute any acknowledgment of the accuracy of the dates or contents of these documents. Furthermore, in any country, any reference to these publications herein does not constitute an endorsement that such publications are part of the general knowledge in the art.
[0443] Although this disclosure has been described in detail above with general descriptions and specific embodiments, modifications or improvements can be made to it, which will be obvious to those skilled in the art. Therefore, such modifications or improvements made without departing from the spirit of this disclosure are all within the scope of protection claimed by this disclosure.
Claims
1. An anti-ActRIIB antibody or an antigen-binding fragment thereof, comprising: HCDR1 comprising the amino acid sequence shown in SEQ ID NO:30, 1, 4, 8, 12, 15, 18, 21, 24 or 27; HCDR2 comprising the amino acid sequence shown in SEQ ID NO:31, 5, 2, 9, 11, 13, 16, 19, 22, 25, 28 or 33; HCDR3 comprising the amino acid sequence shown in SEQ ID NO:32, 7, 3, 6, 10, 14, 17, 20, 23, 26, 29 or 34; LCDR1 comprising the amino acid sequence shown in SEQ ID NO:58, 35, 41, 44, 46, 49, 52 or 55; LCDR2 comprising the amino acid sequence shown in SEQ ID NO:59, 36, 38, 42, 47, 50, 51, 53, 56 or 61; and comprising SEQ ID NO:30, 1, 4, 8, 12, 15, 18, 21, 24 or 27; LCDR3 with amino acid sequences shown in NO:60, 40, 37, 39, 43, 45, 48, 54, 57, 62 or 63.
2. The anti-ActRIIB antibody or antigen-binding fragment thereof of claim 1, wherein, The anti-ActRIIB antibody or its antigen-binding fragment comprises: (1) HCDR1 containing the amino acid sequence shown in SEQ ID NO:30, HCDR2 containing the amino acid sequence shown in SEQ ID NO:31, HCDR3 containing the amino acid sequence shown in SEQ ID NO:32, LCDR1 containing the amino acid sequence shown in SEQ ID NO:58, LCDR2 containing the amino acid sequence shown in SEQ ID NO:59, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
60. (2) HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:7, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
40. (3) HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:2, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
37. (4) HCDR1 containing the amino acid sequence shown in SEQ ID NO:4, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:6, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:38, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
39. (5) HCDR1 containing the amino acid sequence shown in SEQ ID NO:1, HCDR2 containing the amino acid sequence shown in SEQ ID NO:5, HCDR3 containing the amino acid sequence shown in SEQ ID NO:3, LCDR1 containing the amino acid sequence shown in SEQ ID NO:35, LCDR2 containing the amino acid sequence shown in SEQ ID NO:36, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
40. (6) HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:9, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:41, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
43. (7) HCDR1 containing the amino acid sequence shown in SEQ ID NO:8, HCDR2 containing the amino acid sequence shown in SEQ ID NO:11, HCDR3 containing the amino acid sequence shown in SEQ ID NO:10, LCDR1 containing the amino acid sequence shown in SEQ ID NO:44, LCDR2 containing the amino acid sequence shown in SEQ ID NO:42, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
45. (8) HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:47, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
48. (9) HCDR1 containing the amino acid sequence shown in SEQ ID NO:15, HCDR2 containing the amino acid sequence shown in SEQ ID NO:16, HCDR3 containing the amino acid sequence shown in SEQ ID NO:17, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
48. (10) HCDR1 containing the amino acid sequence shown in SEQ ID NO:18, HCDR2 containing the amino acid sequence shown in SEQ ID NO:19, HCDR3 containing the amino acid sequence shown in SEQ ID NO:20, LCDR1 containing the amino acid sequence shown in SEQ ID NO:49, LCDR2 containing the amino acid sequence shown in SEQ ID NO:51, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
48. (11) HCDR1 containing the amino acid sequence shown in SEQ ID NO:21, HCDR2 containing the amino acid sequence shown in SEQ ID NO:22, HCDR3 containing the amino acid sequence shown in SEQ ID NO:23, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
48. (12) HCDR1 containing the amino acid sequence shown in SEQ ID NO:24, HCDR2 containing the amino acid sequence shown in SEQ ID NO:25, HCDR3 containing the amino acid sequence shown in SEQ ID NO:26, LCDR1 containing the amino acid sequence shown in SEQ ID NO:52, LCDR2 containing the amino acid sequence shown in SEQ ID NO:53, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
54. (13) HCDR1 containing the amino acid sequence shown in SEQ ID NO:27, HCDR2 containing the amino acid sequence shown in SEQ ID NO:28, HCDR3 containing the amino acid sequence shown in SEQ ID NO:29, LCDR1 containing the amino acid sequence shown in SEQ ID NO:55, LCDR2 containing the amino acid sequence shown in SEQ ID NO:56, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
57. (14) HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:33, HCDR3 containing the amino acid sequence shown in SEQ ID NO:34, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:61, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:62; or (15) HCDR1 containing the amino acid sequence shown in SEQ ID NO:12, HCDR2 containing the amino acid sequence shown in SEQ ID NO:13, HCDR3 containing the amino acid sequence shown in SEQ ID NO:14, LCDR1 containing the amino acid sequence shown in SEQ ID NO:46, LCDR2 containing the amino acid sequence shown in SEQ ID NO:50, and LCDR3 containing the amino acid sequence shown in SEQ ID NO:
63.
3. An anti-ActRIIB antibody or an antigen-binding fragment thereof, comprising: HCDR1, HCDR2, and HCDR3 in a heavy chain variable region as shown in SEQ ID NO: 88, 70, 64, 66, 68, 72, 74, 76, 78, 80, 82, 84, 86, 90, or 92, and LCDR1, LCDR2, and LCDR3 in a light chain variable region as shown in SEQ ID NO: 89, 71, 65, 67, 69, 73, 75, 77, 79, 81, 83, 85, 87, 91, or 93, wherein the CDRs are defined according to Kabat, IMGT, Chothia, Contact, AbM, and / or CCG.
4. The anti-ActRIIB antibody or antigen-binding fragment thereof of claim 3, wherein, The anti-ActRIIB antibody or its antigen-binding fragment comprises: (1) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:88, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:89; (2) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:70, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:71; (3) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:64, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:65; (4) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:66, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:
67. (5) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:68, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:69; (6) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:72, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:73; (7) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:74, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:75; (8) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:76, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:
77. (9) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:78, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:79; (10) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:80, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:81; (11) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:82, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:83; (12) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:84, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:85; (13) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:86, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:87; (14) HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:90, and LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:91; or (15) HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:92, and LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:93; The CDR is defined according to Kabat, IMGT, Chothia, Contact, AbM and / or CCG.
5. The anti-ActRIIB antibody or antigen-binding fragment thereof of any one of claims 1-4, wherein, The anti-ActRIIB antibody or its antigen-binding fragment comprises a heavy chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with the amino acid sequence shown in SEQ ID NO: 88, 70, 64, 66, 68, 72, 74, 76, 78, 80, or 92.
6. The anti-ActRIIB antibody or antigen-binding fragment thereof of any one of claims 1-5, wherein, The anti-ActRIIB antibody or its antigen-binding fragment comprises a light chain variable region having an amino acid sequence identity of at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% with respect to the amino acid sequences shown in SEQ ID NO: 89, 71, 65, 67, 69, 73, 75, 77, 79, 81, 83, 85%, 87%, 98%, 99%, or 100%.
7. The anti-ActRIIB antibody or antigen-binding fragment thereof of any one of claims 1-6, wherein, The anti-ActRIIB antibody or its antigen-binding fragment comprises: (1) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:88, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:89; (2) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:71; (3) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:65; (4) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:67; (5) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:68, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:69; (6) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:72, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:73; (7) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:74, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:75; (8) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:76, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:77; (9) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:78, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:79; (10) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:80, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:81; (11) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:82, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:83; (12) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:84, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:85; (13) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:86, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:87; (14) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 90, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 91; or (15) A heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:92, and a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:
93.
8. The anti-ActRIIB antibody or antigen-binding fragment thereof of any one of claims 1-7, wherein, The anti-ActRIIB antibody or its antigen-binding fragment comprises: (1) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:88, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:89; (2) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:70, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:71; (3) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:64, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:65; (4) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:66, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:67; (5) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:68 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:69; (6) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:72 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:73; (7) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:74, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:75; (8) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:76, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:77; (9) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:78, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:79; (10) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:80 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:81; (11) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:82 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:83; (12) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:84, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:85; (13) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:86 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:87; (14) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:90, and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:91; or (15) A heavy chain variable region comprising the amino acid sequence shown in SEQ ID NO:92 and a light chain variable region comprising the amino acid sequence shown in SEQ ID NO:
93.
9. The anti-ActRIIB antibody or antigen-binding fragment thereof of any of claims 1-8, wherein, The antigen-binding fragment is a Fab fragment, an F(ab')2 fragment, an Fd fragment, an Fv fragment, a separated CDR region, or a scFv.
10. The anti-ActRIIB antibody or antigen-binding fragment thereof of any one of claims 1-9, wherein, The anti-ActRIIB antibody is an IgG1, IgG2, IgG3 or IgG4 isotype.
11. The anti-ActRIIB antibody or antigen-binding fragment thereof of any one of claims 1-10, wherein, The anti-ActRIIB antibody comprises a heavy chain whose amino acid sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO: 144, 142, 106, 94, 98%, 102%, 118, 122, 126, 130, 134, 138, 148, or 152.
12. The anti-ActRIIB antibody or antigen-binding fragment thereof of any one of claims 1-11, wherein, The anti-ActRIIB antibody comprises a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 146, 108, 96, 100, 104, 112, 116, 120, 124, 128, 132, 136, 140, 150, or 154.
13. The anti-ActRIIB antibody or antigen-binding fragment thereof of any one of claims 1-12, wherein, The anti-ActRIIB antibody comprises: (1) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:144, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:146; (2) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:142, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:146; (3) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:106, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:108; (4) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:94, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:96; (5) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 98, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO: 100; (6) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:102, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:104; (7) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:110, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:112; (8) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:114, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:116; (9) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:118, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:120; (10) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:122, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:124; (11) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:126, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:128; (12) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:130, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:132; (13) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:134, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:136; (14) A heavy chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:138, and a light chain having an amino acid sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence shown in SEQ ID NO:140; (15) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:148, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:150; or (16) A heavy chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:152, and a light chain having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence shown in SEQ ID NO:
154.
14. An anti-ActRIIB antibody or antigen-binding fragment thereof, wherein, The anti-ActRIIB antibody comprises: (1) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:144, and a light chain comprising the amino acid sequence shown in SEQ ID NO:146; (2) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:142, and a light chain comprising the amino acid sequence shown in SEQ ID NO:146; (3) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:106, and a light chain comprising the amino acid sequence shown in SEQ ID NO:108; (4) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:94, and a light chain comprising the amino acid sequence shown in SEQ ID NO:96; (5) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:98, and a light chain comprising the amino acid sequence shown in SEQ ID NO:100; (6) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:102, and a light chain comprising the amino acid sequence shown in SEQ ID NO:104; (7) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:110, and a light chain comprising the amino acid sequence shown in SEQ ID NO:112; (8) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:114, and a light chain comprising the amino acid sequence shown in SEQ ID NO:116; (9) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:118, and a light chain comprising the amino acid sequence shown in SEQ ID NO:120; (10) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:122, and a light chain comprising the amino acid sequence shown in SEQ ID NO:124; (11) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:126, and a light chain comprising the amino acid sequence shown in SEQ ID NO:128; (12) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:130, and a light chain comprising the amino acid sequence shown in SEQ ID NO:132; (13) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:134, and a light chain comprising the amino acid sequence shown in SEQ ID NO:136; (14) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:138, and a light chain comprising the amino acid sequence shown in SEQ ID NO:140; (15) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:148, and a light chain comprising the amino acid sequence shown in SEQ ID NO:150; or (16) A heavy chain comprising the amino acid sequence shown in SEQ ID NO:152, and a light chain comprising the amino acid sequence shown in SEQ ID NO:
154.
15. The anti-ActRIIB antibody or antigen-binding fragment thereof of any one of claims 1-14, wherein, The anti-ActRIIB antibody or its antigen-binding fragment has one or more of the following properties: (1) Human ActRIIB; preferably, measured by surface plasmon resonance technology, with a KD of 1.00E-08M or less, 9.00E-09M or less, 8.00E-09M or less, or 7.00E-09M or less; (2) ActRIIA (non-conjugated or largely non-conjugated persons); (3) Competing with ActivinA, GDF8 and / or GDF11 to bind to human ActRIIB; (4) Promotes muscle formation; (5) Reduce fat formation; (6) Induces tumor growth and regression in vivo; and (7) Delay the growth of tumors in the body.
16. An isolated nucleic acid comprising a nucleotide sequence encoding an anti-ActRIIB antibody or an antigen-binding fragment thereof as described in any one of claims 1-15.
17. A vector comprising the nucleic acid of claim 16.
18. A host cell comprising the nucleic acid of claim 16 or the vector of claim 17.
19. A method for preparing an anti-ActRIIB antibody or an antigen-binding fragment thereof according to any one of claims 1-15, comprising culturing the host cell of claim 18 to express the anti-ActRIIB antibody or the antigen-binding fragment thereof, and isolating and purifying the anti-ActRIIB antibody or the antigen-binding fragment thereof in the system.
20. A fusion protein comprising the anti-ActRIIB antibody or its antigen-binding fragment as described in any one of claims 1-15.
21. An antibody-drug conjugate comprising the anti-ActRIIB antibody or its antigen-binding fragment as described in any one of claims 1-15.
22. A chimeric antigen receptor comprising the anti-ActRIIB antibody or its antigen-binding fragment as described in any one of claims 1-15.
23. An engineered immune effector cell comprising the chimeric antigen receptor of claim 22.
24. A pharmaceutical composition comprising an anti-ActRIIB antibody or an antigen-binding fragment thereof according to any one of claims 1-15, a fusion protein according to claim 20, an antibody-drug conjugate according to claim 21, or an engineered immune effector cell according to claim 23; optionally, the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients.
25. Use of the anti-ActRIIB antibody or antigen-binding fragment thereof according to any one of claims 1-15, the fusion protein according to claim 20, the antibody-drug conjugate according to claim 21, the engineered immune effector cell according to claim 23, or the pharmaceutical composition according to claim 24 in the preparation of a medicament for treating diseases related to ActRII expression or ActRII signaling.
26. The use of claim 25, wherein, The diseases mentioned are musculoskeletal system diseases, endocrine and metabolic system diseases, immune system diseases, blood diseases, cardiovascular system diseases, fibrotic diseases and / or tumors.
27. Use according to claim 25 or 26, wherein, The diseases mentioned are myositis, sarcopenia, muscle atrophy, muscular dystrophy, muscle loss, osteoporosis, bone loss, diabetes, obesity, non-alcoholic steatohepatitis, cirrhosis, autoimmune diseases, anemia, pulmonary hypertension, heart failure, liver fibrosis, pulmonary fibrosis, renal fibrosis, vascular fibrosis, and / or tumors.
28. A method of treating a disease associated with ActRII expression or ActRII signaling, comprising administering to a subject an anti-ActRIIB antibody or an antigen-binding fragment thereof as described in any one of claims 1-15, a fusion protein as described in claim 20, an antibody-drug conjugate as described in claim 21, engineered immune effector cells as described in claim 23, or a pharmaceutical composition as described in claim 24.
29. The method of claim 28, wherein, The diseases mentioned are musculoskeletal system diseases, endocrine and metabolic system diseases, immune system diseases, blood diseases, cardiovascular system diseases, fibrotic diseases and / or tumors.
30. The method of claim 28 or 29, wherein, The diseases mentioned are myositis, sarcopenia, muscle atrophy, muscular dystrophy, muscle loss, osteoporosis, bone loss, diabetes, obesity, non-alcoholic steatohepatitis, cirrhosis, autoimmune diseases, anemia, pulmonary hypertension, heart failure, liver fibrosis, pulmonary fibrosis, renal fibrosis, vascular fibrosis, and / or tumors.
31. A kit comprising the anti-ActRIIB antibody or its antigen-binding fragment as described in any one of claims 1-15, the fusion protein as described in claim 20, the antibody-drug conjugate as described in claim 21, the engineered immune effector cells as described in claim 23, or the pharmaceutical composition as described in claim 24.
